{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:49Z","timestamp":1786982689657,"version":"build-2736575974"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Nutr Rep"],"DOI":"10.1007\/s13668-023-00452-5","type":"journal-article","created":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T09:23:44Z","timestamp":1674897824000},"page":"181-190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Responses to Hypoxia: How Fructose Metabolism and Hypoxia-Inducible Factor-1a Pathways Converge in Health and Disease"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-0675","authenticated-orcid":false,"given":"Mehmet","family":"Kanbay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alara","family":"Alt\u0131ntas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furkan","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidar","family":"Copur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura G.","family":"Sanchez-Lozada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Lanaspa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,28]]},"reference":[{"key":"452_CR1","volume-title":"Hypoxia","author":"BS Bhutta","year":"2021","unstructured":"Bhutta BS, Alghoula F, Berim I. Hypoxia. Treasure island (FL): StatPearls; 2021."},{"issue":"24","key":"452_CR2","doi-asserted-by":"publisher","first-page":"9361","DOI":"10.1128\/MCB.23.24.9361-9374.2003","volume":"23","author":"CJ Hu","year":"2003","unstructured":"Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol. 2003;23(24):9361\u201374.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"452_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/emm.2004.1","volume":"36","author":"JW Lee","year":"2004","unstructured":"Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW. Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med. 2004;36(1):1\u201312.","journal-title":"Exp Mol Med"},{"issue":"6","key":"452_CR4","first-page":"1425","volume":"54","author":"AC Koong","year":"1994","unstructured":"Koong AC, Chen EY, Giaccia AJ. Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res. 1994;54(6):1425\u201330.","journal-title":"Cancer Res"},{"issue":"20","key":"452_CR5","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1128\/MCB.00409-10","volume":"30","author":"C Culver","year":"2010","unstructured":"Culver C, Sundqvist A, Mudie S, Melvin A, Xirodimas D, Rocha S. Mechanism of hypoxia-induced NF-kappaB. Mol Cell Biol. 2010;30(20):4901\u201321.","journal-title":"Mol Cell Biol"},{"issue":"5","key":"452_CR6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","volume":"5","author":"GN Masoud","year":"2015","unstructured":"Masoud GN, Li W. HIF-1\u03b1 pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5(5):378\u201389.","journal-title":"Acta Pharm Sin B"},{"issue":"9","key":"452_CR7","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1210\/clinem\/dgab362","volume":"106","author":"J Min","year":"2021","unstructured":"Min J, Zeng T, Roux M, Lazar D, Chen L, Tudzarova S. The role of HIF1\u03b1-PFKFB3 pathway in diabetic retinopathy. J Clin Endocrinol Metab. 2021;106(9):2505\u201319.","journal-title":"J Clin Endocrinol Metab"},{"key":"452_CR8","doi-asserted-by":"crossref","unstructured":"\u2022 Nomoto H, Pei L, Montemurro C, Rosenberger M, Furterer A, Coppola G, et al. Activation of the HIF1\u03b1\/PFKFB3 stress response pathway in beta cells in type 1 diabetes. Diabetologia. 2020;63(1):149\u201361. The conserved pro-survival HIF1\u03b1-mediated injury-response signalling is activated in beta cells in type 1 diabetes and likely contributes to the relatively slow rate of beta cell loss at the expense of early defective glucose-induced insulin secretion.","DOI":"10.1007\/s00125-019-05030-5"},{"issue":"1","key":"452_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1113\/JP280572","volume":"599","author":"S Kierans","year":"2021","unstructured":"Kierans S, Taylor C. Regulation of glycolysis by the hypoxia-inducible factor (HIF): implications for cellular physiology. J Physiol. 2021;599(1):23\u201337.","journal-title":"J Physiol"},{"key":"452_CR10","doi-asserted-by":"crossref","unstructured":"\u2022 McGettrick AF, O'Neill LAJ. The role of HIF in immunity and inflammation. Cell Metab. 2020;32(4):524\u201336. HIF is one of the key regulator of immune cell function.","DOI":"10.1016\/j.cmet.2020.08.002"},{"issue":"4","key":"452_CR11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.immuni.2014.09.008","volume":"41","author":"A Palazon","year":"2014","unstructured":"Palazon A, Goldrath AW, Nizet V, Johnson RS. HIF transcription factors, inflammation, and immunity. Immunity. 2014;41(4):518\u201328.","journal-title":"Immunity"},{"issue":"3","key":"452_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/joim.12993","volume":"287","author":"RJ Johnson","year":"2020","unstructured":"Johnson RJ, Stenvinkel P, Andrews P, Sanchez-Lozada LG, Nakagawa T, Gaucher E, et al. Fructose metabolism as a common evolutionary pathway of survival associated with climate change, food shortage and droughts. J Intern Med. 2020;287(3):252\u201362.","journal-title":"J Intern Med"},{"issue":"2","key":"452_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/ncpneph0019","volume":"1","author":"T Nakagawa","year":"2005","unstructured":"Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol. 2005;1(2):80\u20136.","journal-title":"Nat Clin Pract Nephrol"},{"issue":"7515","key":"452_CR14","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S0140-6736(67)90494-1","volume":"2","author":"J Perheentupa","year":"1967","unstructured":"Perheentupa J, Raivio K. Fructose-induced hyperuricaemia. Lancet. 1967;2(7515):528\u201331.","journal-title":"Lancet"},{"issue":"8","key":"452_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/0026-0495(72)90120-5","volume":"21","author":"IH Fox","year":"1972","unstructured":"Fox IH, Kelley WN. Studies on the mechanism of fructose-induced hyperuricemia in man. Metabolism. 1972;21(8):713\u201321.","journal-title":"Metabolism"},{"issue":"3","key":"452_CR16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1042\/bj1620601","volume":"162","author":"G van den Berghe","year":"1977","unstructured":"van den Berghe G, Bronfman M, Vanneste R, Hers HG. The mechanism of adenosine triphosphate depletion in the liver after a load of fructose. A kinetic study of liver adenylate deaminase. Biochem J. 1977;162(3):601\u20139.","journal-title":"Biochem J"},{"issue":"3","key":"452_CR17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1136\/ard.33.3.276","volume":"33","author":"BT Emmerson","year":"1974","unstructured":"Emmerson BT. Effect of oral fructose on urate production. Ann Rheum Dis. 1974;33(3):276\u201380.","journal-title":"Ann Rheum Dis"},{"issue":"5 Suppl","key":"452_CR18","doi-asserted-by":"publisher","first-page":"754S","DOI":"10.1093\/ajcn\/58.5.754S","volume":"58","author":"PA Mayes","year":"1993","unstructured":"Mayes PA. Intermediary metabolism of fructose. Am J Clin Nutr. 1993;58(5 Suppl):754S-S765.","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"452_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1743-7075-9-89","volume":"9","author":"SZ Sun","year":"2012","unstructured":"Sun SZ, Empie MW. Fructose metabolism in humans - what isotopic tracer studies tell us. Nutr Metab (Lond). 2012;9(1):89.","journal-title":"Nutr Metab (Lond)"},{"issue":"6335","key":"452_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1126\/science.aab3896","volume":"356","author":"TJ Park","year":"2017","unstructured":"Park TJ, Reznick J, Peterson BL, Blass G, Omerbasic D, Bennett NC, et al. Fructose-driven glycolysis supports anoxia resistance in the naked mole-rat. Science. 2017;356(6335):307\u201311.","journal-title":"Science"},{"key":"452_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40170-020-00222-9","volume":"8","author":"T Nakagawa","year":"2020","unstructured":"Nakagawa T, Lanaspa MA, Millan IS, Fini M, Rivard CJ, Sanchez-Lozada LG, et al. Fructose contributes to the Warburg effect for cancer growth. Cancer Metab. 2020;8:16.","journal-title":"Cancer Metab"},{"issue":"6433","key":"452_CR22","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.aat8515","volume":"363","author":"MD Goncalves","year":"2019","unstructured":"Goncalves MD, Lu C, Tutnauer J, Hartman TE, Hwang SK, Murphy CJ, et al. High-fructose corn syrup enhances intestinal tumor growth in mice. Science. 2019;363(6433):1345\u20139.","journal-title":"Science"},{"issue":"12","key":"452_CR23","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1073\/pnas.1713837115","volume":"115","author":"MA Lanaspa","year":"2018","unstructured":"Lanaspa MA, Kuwabara M, Andres-Hernando A, Li N, Cicerchi C, Jensen T, et al. High salt intake causes leptin resistance and obesity in mice by stimulating endogenous fructose production and metabolism. Proc Natl Acad Sci USA. 2018;115(12):3138\u201343.","journal-title":"Proc Natl Acad Sci USA"},{"key":"452_CR24","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1038\/ncomms3434","volume":"4","author":"MA Lanaspa","year":"2013","unstructured":"Lanaspa MA, Ishimoto T, Li N, Cicerchi C, Orlicky DJ, Ruzycki P, et al. Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome. Nat Commun. 2013;4:2434.","journal-title":"Nat Commun"},{"key":"452_CR25","doi-asserted-by":"publisher","first-page":"14181","DOI":"10.1038\/ncomms14181","volume":"8","author":"A Andres-Hernando","year":"2017","unstructured":"Andres-Hernando A, Li N, Cicerchi C, Inaba S, Chen W, Roncal-Jimenez C, et al. Protective role of fructokinase blockade in the pathogenesis of acute kidney injury in mice. Nat Commun. 2017;8:14181.","journal-title":"Nat Commun"},{"issue":"2","key":"452_CR26","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/ki.2013.492","volume":"86","author":"CA Roncal Jimenez","year":"2014","unstructured":"Roncal Jimenez CA, Ishimoto T, Lanaspa MA, Rivard CJ, Nakagawa T, Ejaz AA, et al. Fructokinase activity mediates dehydration-induced renal injury. Kidney Int. 2014;86(2):294\u2013302.","journal-title":"Kidney Int"},{"issue":"11","key":"452_CR27","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1681\/ASN.2013080901","volume":"25","author":"MA Lanaspa","year":"2014","unstructured":"Lanaspa MA, Ishimoto T, Cicerchi C, Tamura Y, Roncal-Jimenez CA, Chen W, et al. Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy. J Am Soc Nephrol. 2014;25(11):2526\u201338.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"452_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1056\/NEJM198501173120305","volume":"312","author":"JM McCord","year":"1985","unstructured":"McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985;312(3):159\u201363.","journal-title":"N Engl J Med"},{"issue":"8","key":"452_CR29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1369\/jhc.2009.953190","volume":"57","author":"CP Diggle","year":"2009","unstructured":"Diggle CP, Shires M, Leitch D, Brooke D, Carr IM, Markham AF, et al. Ketohexokinase: expression and localization of the principal fructose-metabolizing enzyme. J Histochem Cytochem. 2009;57(8):763\u201374.","journal-title":"J Histochem Cytochem"},{"issue":"7557","key":"452_CR30","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/nature14508","volume":"522","author":"P Mirtschink","year":"2015","unstructured":"Mirtschink P, Krishnan J, Grimm F, Sarre A, H\u00f6rl M, Kayikci M, et al. HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease. Nature. 2015;522(7557):444\u20139.","journal-title":"Nature"},{"key":"452_CR31","doi-asserted-by":"publisher","unstructured":"Mirtschink P, Krek W. Hypoxia-driven glycolytic and fructolytic metabolic programs: Pivotal to hypertrophic heart disease. Biochim Biophys Acta. 2016 Jul;1863(7 Pt B):1822-8. https:\/\/doi.org\/10.1016\/j.bbamcr.2016.02.011. Epub 2016 Feb 16. PMID: 26896647.","DOI":"10.1016\/j.bbamcr.2016.02.011"},{"key":"452_CR32","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3389\/fcell.2020.00566","volume":"8","author":"T Eberhart","year":"2020","unstructured":"Eberhart T, Sch\u00f6nenberger MJ, Walter KM, Charles KN, Faust PL, Kovacs WJ. Peroxisome-deficiency and HIF-2\u03b1 signaling are negative regulators of ketohexokinase expression. Front Cell Dev Biol. 2020;8:566.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"452_CR33","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.bbrc.2007.07.032","volume":"361","author":"IS Wood","year":"2007","unstructured":"Wood IS, Wang B, Lorente-Cebrian S, Trayhurn P. Hypoxia increases expression of selective facilitative glucose transporters (GLUT) and 2-deoxy-D-glucose uptake in human adipocytes. Biochem Biophys Res Commun. 2007;361(2):468\u201373.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7 Pt B","key":"452_CR34","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.bbamcr.2016.02.011","volume":"1863","author":"P Mirtschink","year":"2016","unstructured":"Mirtschink P, Krek W. Hypoxia-driven glycolytic and fructolytic metabolic programs: pivotal to hypertrophic heart disease. Biochim Biophys Acta. 2016;1863(7 Pt B):1822\u20138.","journal-title":"Biochim Biophys Acta"},{"issue":"26","key":"452_CR35","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1093\/eurheartj\/ehx518","volume":"39","author":"P Mirtschink","year":"2018","unstructured":"Mirtschink P, Jang C, Arany Z, Krek W. Fructose metabolism, cardiometabolic risk, and the epidemic of coronary artery disease. Eur Heart J. 2018;39(26):2497\u2013505.","journal-title":"Eur Heart J"},{"key":"452_CR36","doi-asserted-by":"publisher","unstructured":"Doke T, Ishimoto T, Hayasaki T, Ikeda S, Hasebe M, Hirayama A, Soga T, Kato N, Kosugi T, Tsuboi N, Lanaspa MA, Johnson RJ, Kadomatsu K, Maruyama S. Lacking ketohexokinase-A exacerbates renal injury in streptozotocin-induced diabetic mice. Metabolism. 2018 Aug;85:161-170. https:\/\/doi.org\/10.1016\/j.metabol.2018.03.020. Epub 2018 Mar 29. PMID: 29604362; PMCID: PMC6394855.","DOI":"10.1016\/j.metabol.2018.03.020"},{"key":"452_CR37","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.10604","volume":"9","author":"I Baryla","year":"2021","unstructured":"Baryla I, Pluciennik E, Ko\u015bla K, Wojcik M, Zieleniak A, Zurawska-Klis M, et al. Identification of a novel association for the WWOX\/HIF1A axis with gestational diabetes mellitus (GDM). PeerJ. 2021;9:e10604.","journal-title":"PeerJ"},{"key":"452_CR38","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Moldogazieva NT, Mokhosoev IM, Terentiev AA. Metabolic heterogeneity of cancer cells: an interplay between HIF-1, GLUTs, and AMPK. Cancers. 2020;12(4):862. Hypoxia-inducible factor-1 (HIF-1) and AMP-activated protein kinase (AMPK) represent key modulators of a switch between reprogrammed and oxidative metabolism.","DOI":"10.3390\/cancers12040862"},{"issue":"5","key":"452_CR39","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","volume":"68","author":"T Jensen","year":"2018","unstructured":"Jensen T, Abdelmalek MF, Sullivan S, Nadeau KJ, Green M, Roncal C, et al. Fructose and sugar: a major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018;68(5):1063\u201375.","journal-title":"J Hepatol"},{"issue":"15","key":"452_CR40","doi-asserted-by":"publisher","first-page":"7841","DOI":"10.3390\/ijms22157841","volume":"22","author":"CH Wang","year":"2021","unstructured":"Wang CH, Liu HM, Chang ZY, Huang TH, Lee TY. Losartan prevents hepatic steatosis and macrophage polarization by inhibiting HIF-1alpha in a murine model of NAFLD. Int J Mol Sci. 2021;22(15):7841.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"452_CR41","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/s41467-017-01965-8","volume":"8","author":"W Du","year":"2017","unstructured":"Du W, Zhang L, Brett-Morris A, Aguila B, Kerner J, Hoppel CL, et al. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. Nat Commun. 2017;8(1):1769.","journal-title":"Nat Commun"},{"issue":"1","key":"452_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1681\/ASN.2005070757","volume":"17","author":"M Nangaku","year":"2006","unstructured":"Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17(1):17\u201325.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"452_CR43","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.2337\/db20-0457","volume":"69","author":"C Vinovskis","year":"2020","unstructured":"Vinovskis C, Li LP, Prasad P, Tommerdahl K, Pyle L, Nelson RG, et al. Relative hypoxia and early diabetic kidney disease in type 1 diabetes. Diabetes. 2020;69(12):2700\u20138.","journal-title":"Diabetes"},{"issue":"5","key":"452_CR44","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3390\/ijms18050950","volume":"18","author":"J Liu","year":"2017","unstructured":"Liu J, Wei Q, Guo C, Dong G, Liu Y, Tang C, et al. Hypoxia, HIF, and associated signaling networks in chronic kidney disease. Int J Mol Sci. 2017;18(5):950.","journal-title":"Int J Mol Sci"},{"issue":"6779","key":"452_CR45","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/35008121","volume":"404","author":"T Nishikawa","year":"2000","unstructured":"Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404(6779):787\u201390.","journal-title":"Nature"},{"key":"452_CR46","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/696215","volume":"2012","author":"A Naudi","year":"2012","unstructured":"Naudi A, Jove M, Ayala V, Cassanye A, Serrano J, Gonzalo H, et al. Cellular dysfunction in diabetes as maladaptive response to mitochondrial oxidative stress. Exp Diabetes Res. 2012;2012:696215.","journal-title":"Exp Diabetes Res"},{"issue":"3","key":"452_CR47","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2337\/db14-0874","volume":"64","author":"K Sharma","year":"2015","unstructured":"Sharma K. Mitochondrial hormesis and diabetic complications. Diabetes. 2015;64(3):663\u201372.","journal-title":"Diabetes"},{"issue":"15","key":"452_CR48","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.86976","volume":"1","author":"KM Sas","year":"2016","unstructured":"Sas KM, Kayampilly P, Byun J, Nair V, Hinder LM, Hur J, et al. Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications. JCI Insight. 2016;1(15):e86976.","journal-title":"JCI Insight"},{"issue":"11","key":"452_CR49","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1681\/ASN.2013020126","volume":"24","author":"K Sharma","year":"2013","unstructured":"Sharma K, Karl B, Mathew AV, Gangoiti JA, Wassel CL, Saito R, et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol. 2013;24(11):1901\u201312.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"452_CR50","doi-asserted-by":"publisher","first-page":"F561","DOI":"10.1152\/ajprenal.00036.2017","volume":"313","author":"H Ding","year":"2017","unstructured":"Ding H, Jiang L, Xu J, Bai F, Zhou Y, Yuan Q, et al. Inhibiting aerobic glycolysis suppresses renal interstitial fibroblast activation and renal fibrosis. Am J Physiol Renal Physiol. 2017;313(3):F561\u201375.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"452_CR51","doi-asserted-by":"publisher","first-page":"F722","DOI":"10.1152\/ajprenal.00306.2016","volume":"311","author":"CA Roncal-Jimenez","year":"2016","unstructured":"Roncal-Jimenez CA, Ishimoto T, Lanaspa MA, Milagres T, Hernando AA, Jensen T, et al. Aging-associated renal disease in mice is fructokinase dependent. Am J Physiol Renal Physiol. 2016;311(4):F722\u201330.","journal-title":"Am J Physiol Renal Physiol"},{"key":"452_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102108","volume":"46","author":"TS Lee","year":"2021","unstructured":"Lee TS, Lu TM, Chen CH, Guo BC, Hsu CP. Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine\/dimethylarginine dimethyl aminotransferase 2 pathway. Redox Biol. 2021;46:102108.","journal-title":"Redox Biol"},{"key":"452_CR53","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.atherosclerosis.2018.10.007","volume":"278","author":"T Maruhashi","year":"2018","unstructured":"Maruhashi T, Hisatome I, Kihara Y, Higashi Y. Hyperuricemia and endothelial function: From molecular background to clinical perspectives. Atherosclerosis. 2018;278:226\u201331.","journal-title":"Atherosclerosis"},{"issue":"3\u20134","key":"452_CR54","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1159\/000345509","volume":"121","author":"LG Sanchez-Lozada","year":"2012","unstructured":"Sanchez-Lozada LG, Lanaspa MA, Cristobal-Garcia M, Garcia-Arroyo F, Soto V, Cruz-Robles D, et al. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol. 2012;121(3\u20134):e71\u20138.","journal-title":"Nephron Exp Nephrol"},{"issue":"1","key":"452_CR55","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00074.x","volume":"67","author":"LG Sanchez-Lozada","year":"2005","unstructured":"Sanchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Soto V, Nepomuceno T, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005;67(1):237\u201347.","journal-title":"Kidney Int"},{"issue":"5","key":"452_CR56","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1161\/HYPERTENSIONAHA.111.175315","volume":"58","author":"MC Foster","year":"2011","unstructured":"Foster MC, Hwang SJ, Porter SA, Massaro JM, Hoffmann U, Fox CS. Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study. Hypertension. 2011;58(5):784\u201390.","journal-title":"Hypertension"},{"issue":"9","key":"452_CR57","first-page":"648","volume":"16","author":"H A\u015fc\u0131","year":"2016","unstructured":"A\u015fc\u0131 H, Sayg\u0131n M, Ye\u015filot \u015e, Topsakal \u015e, Cankara FN, \u00d6zmen \u00d6, et al. Protective effects of aspirin and vitamin C against corn syrup consumption-induced cardiac damage through sirtuin-1 and HIF-1\u03b1 pathway. Anatol J Cardiol. 2016;16(9):648\u201354.","journal-title":"Anatol J Cardiol"},{"issue":"6","key":"452_CR58","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1159\/000503926","volume":"44","author":"J Tanabe","year":"2019","unstructured":"Tanabe J, Ogura Y, Nakabayashi M, Nagai Y, Watanabe S, Sugaya T, et al. The possibility of urinary liver-type fatty acid-binding protein as a biomarker of renal hypoxia in spontaneously diabetic torii fatty rats. Kidney Blood Press Res. 2019;44(6):1476\u201392.","journal-title":"Kidney Blood Press Res"},{"key":"452_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.694457","volume":"12","author":"T Nakagawa","year":"2021","unstructured":"Nakagawa T, Sanchez-Lozada LG, Andres-Hernando A, Kojima H, Kasahara M, Rodriguez-Iturbe B, et al. Endogenous fructose metabolism could explain the Warburg effect and the protection of SGLT2 inhibitors in chronic kidney disease. Front Immunol. 2021;12:694457.","journal-title":"Front Immunol"},{"issue":"1","key":"452_CR60","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41581-020-00350-x","volume":"17","author":"A Marton","year":"2021","unstructured":"Marton A, Kaneko T, Kovalik JP, Yasui A, Nishiyama A, Kitada K, et al. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. Nat Rev Nephrol. 2021;17(1):65\u201377.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"452_CR61","doi-asserted-by":"publisher","first-page":"14754","DOI":"10.1038\/s41598-019-51343-1","volume":"9","author":"R Bessho","year":"2019","unstructured":"Bessho R, Takiyama Y, Takiyama T, Kitsunai H, Takeda Y, Sakagami H, et al. Hypoxia-inducible factor-1alpha is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. Sci Rep. 2019;9(1):14754.","journal-title":"Sci Rep"},{"issue":"5","key":"452_CR62","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41419-020-2544-7","volume":"11","author":"T Cai","year":"2020","unstructured":"Cai T, Ke Q, Fang Y, Wen P, Chen H, Yuan Q, et al. Sodium-glucose cotransporter 2 inhibition suppresses HIF-1alpha-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice. Cell Death Dis. 2020;11(5):390.","journal-title":"Cell Death Dis"},{"issue":"17","key":"452_CR63","first-page":"6548","volume":"61","author":"N Akakura","year":"2001","unstructured":"Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 2001;61(17):6548\u201354.","journal-title":"Cancer Res"},{"issue":"9","key":"452_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024179","volume":"6","author":"M Seo","year":"2011","unstructured":"Seo M, Kim JD, Neau D, Sehgal I, Lee YH. Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect. PLoS ONE. 2011;6(9):e24179.","journal-title":"PLoS ONE"},{"issue":"11","key":"452_CR65","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.3390\/cells10112913","volume":"10","author":"R Alvarez","year":"2021","unstructured":"Alvarez R, Mandal D, Chittiboina P. Canonical and non-canonical roles of PFKFB3 in brain tumors. Cells. 2021;10(11):2913.","journal-title":"Cells"},{"issue":"3","key":"452_CR66","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.bbrc.2016.05.026","volume":"476","author":"H Zhang","year":"2016","unstructured":"Zhang H, Lu C, Fang M, Yan W, Chen M, Ji Y, et al. HIF-1\u03b1 activates hypoxia-induced PFKFB4 expression in human bladder cancer cells. Biochem Biophys Res Commun. 2016;476(3):146\u201352.","journal-title":"Biochem Biophys Res Commun"},{"key":"452_CR67","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/764250","volume":"2015","author":"S Yan","year":"2015","unstructured":"Yan S, Zhang P, Xu W, Liu Y, Wang B, Jiang T, et al. Serum uric acid increases risk of cancer incidence and mortality: a systematic review and meta-analysis. Mediators Inflamm. 2015;2015:764250.","journal-title":"Mediators Inflamm"},{"issue":"6","key":"452_CR68","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1373\/clinchem.2016.268185","volume":"63","author":"CJ Kobylecki","year":"2017","unstructured":"Kobylecki CJ, Afzal S, Nordestgaard BG. Plasma urate, cancer incidence, and all-cause mortality: a Mendelian randomization study. Clin Chem. 2017;63(6):1151\u201360.","journal-title":"Clin Chem"},{"issue":"1","key":"452_CR69","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40170-021-00268-3","volume":"9","author":"MA Fini","year":"2021","unstructured":"Fini MA, Lanaspa MA, Gaucher EA, Boutwell B, Nakagawa T, Wright RM, et al. Brief report: the uricase mutation in humans increases our risk for cancer growth. Cancer Metab. 2021;9(1):32.","journal-title":"Cancer Metab"},{"issue":"7","key":"452_CR70","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.it.2021.05.004","volume":"42","author":"LP Pral","year":"2021","unstructured":"Pral LP, Fachi JL, Correa RO, Colonna M, Vinolo MAR. Hypoxia and HIF-1 as key regulators of gut microbiota and host interactions. Trends Immunol. 2021;42(7):604\u201321.","journal-title":"Trends Immunol"},{"issue":"10","key":"452_CR71","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s42255-020-0261-2","volume":"2","author":"J Todoric","year":"2020","unstructured":"Todoric J, Di Caro G, Reibe S, Henstridge DC, Green CR, Vrbanac A, et al. Fructose stimulated de novo lipogenesis is promoted by inflammation. Nat Metab. 2020;2(10):1034\u201345.","journal-title":"Nat Metab"},{"issue":"5","key":"452_CR72","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.chom.2015.03.005","volume":"17","author":"CJ Kelly","year":"2015","unstructured":"Kelly CJ, Zheng L, Campbell EL, Saeedi B, Scholz CC, Bayless AJ, et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe. 2015;17(5):662\u201371.","journal-title":"Cell Host Microbe"},{"issue":"2","key":"452_CR73","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jevs.2012.05.004","volume":"33","author":"RJ Johnson","year":"2013","unstructured":"Johnson RJ, Rivard C, Lanaspa MA, Otabachian-Smith S, Ishimoto T, Cicerchi C, et al. Fructokinase, fructans, intestinal permeability, and metabolic syndrome: an equine connection? J Equine Vet Science. 2013;33(2):120\u20136.","journal-title":"J Equine Vet Science"},{"issue":"1","key":"452_CR74","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/s41467-021-21461-4","volume":"12","author":"N Jones","year":"2021","unstructured":"Jones N, Blagih J, Zani F, Rees A, Hill DG, Jenkins BJ, et al. Fructose reprogrammes glutamine-dependent oxidative metabolism to support LPS-induced inflammation. Nat Commun. 2021;12(1):1209.","journal-title":"Nat Commun"},{"issue":"2","key":"452_CR75","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41584-019-0334-3","volume":"16","author":"LAB Joosten","year":"2020","unstructured":"Joosten LAB, Crisan TO, Bjornstad P, Johnson RJ. Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat Rev Rheumatol. 2020;16(2):75\u201386.","journal-title":"Nat Rev Rheumatol"},{"key":"452_CR76","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-immunol-032414-112306","volume":"33","author":"MG Netea","year":"2015","unstructured":"Netea MG, van de Veerdonk FL, van der Meer JW, Dinarello CA, Joosten LA. Inflammasome-independent regulation of IL-1-family cytokines. Annu Rev Immunol. 2015;33:49\u201377.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"452_CR77","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1161\/01.HYP.0000072820.07472.3B","volume":"41","author":"J Kanellis","year":"2003","unstructured":"Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41(6):1287\u201393.","journal-title":"Hypertension"},{"issue":"3","key":"452_CR78","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nrneph.2015.193","volume":"12","author":"PH Maxwell","year":"2016","unstructured":"Maxwell PH, Eckardt KU. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol. 2016;12(3):157\u201368.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"452_CR79","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000454818","volume":"45","author":"T Akizawa","year":"2017","unstructured":"Akizawa T, Tsubakihara Y, Nangaku M, Endo Y, Nakajima H, Kohno T, et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. Am J Nephrol. 2017;45(2):127\u201335.","journal-title":"Am J Nephrol"},{"issue":"1","key":"452_CR80","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ckj\/sfy014","volume":"12","author":"AM Meadowcroft","year":"2019","unstructured":"Meadowcroft AM, Cizman B, Holdstock L, Biswas N, Johnson BM, Jones D, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clin Kidney J. 2019;12(1):139\u201348.","journal-title":"Clin Kidney J"},{"issue":"4","key":"452_CR81","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1681\/ASN.2014111139","volume":"27","author":"L Holdstock","year":"2016","unstructured":"Holdstock L, Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol. 2016;27(4):1234\u201344.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"452_CR82","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000464476","volume":"45","author":"ER Martin","year":"2017","unstructured":"Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM. Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am J Nephrol. 2017;45(5):380\u20138.","journal-title":"Am J Nephrol"},{"issue":"5","key":"452_CR83","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","volume":"90","author":"PE Pergola","year":"2016","unstructured":"Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016;90(5):1115\u201322.","journal-title":"Kidney Int"},{"issue":"2","key":"452_CR84","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000500487","volume":"143","author":"T Akizawa","year":"2019","unstructured":"Akizawa T, Nangaku M, Yamaguchi T, Arai M, Koretomo R, Maeda K, et al. Enarodustat, conversion and maintenance therapy for anemia in hemodialysis patients: a randomized, placebo-controlled phase 2b trial followed by long-term trial. Nephron. 2019;143(2):77\u201385.","journal-title":"Nephron"},{"issue":"10","key":"452_CR85","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","volume":"30","author":"A Besarab","year":"2015","unstructured":"Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30(10):1665\u201373.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"452_CR86","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","volume":"32","author":"N Chen","year":"2017","unstructured":"Chen N, Qian J, Chen J, Yu X, Mei C, Hao C, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant. 2017;32(8):1373\u201386.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"452_CR87","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000499111","volume":"49","author":"T Akizawa","year":"2019","unstructured":"Akizawa T, Macdougall IC, Berns JS, Bernhardt T, Staedtler G, Taguchi M, et al. Long-term efficacy and safety of molidustat for anemia in chronic kidney disease: DIALOGUE extension studies. Am J Nephrol. 2019;49(4):271\u201380.","journal-title":"Am J Nephrol"},{"issue":"6","key":"452_CR88","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1159\/000500232","volume":"49","author":"DV Parmar","year":"2019","unstructured":"Parmar DV, Kansagra KA, Patel JC, Joshi SN, Sharma NS, Shelat AD, et al. Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study. Am J Nephrol. 2019;49(6):470\u20138.","journal-title":"Am J Nephrol"},{"issue":"1","key":"452_CR89","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2215\/CJN.02510218","volume":"14","author":"IC Macdougall","year":"2019","unstructured":"Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T. Effects of molidustat in the treatment of anemia in CKD. Clin J Am Soc Nephrol. 2019;14(1):28\u201339.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"452_CR90","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/ckj\/sfy013","volume":"12","author":"L Holdstock","year":"2019","unstructured":"Holdstock L, Cizman B, Meadowcroft AM, Biswas N, Johnson BM, Jones D, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clin Kidney J. 2019;12(1):129\u201338.","journal-title":"Clin Kidney J"},{"issue":"11","key":"452_CR91","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381(11):1011\u201322.","journal-title":"N Engl J Med"},{"issue":"6","key":"452_CR92","doi-asserted-by":"publisher","first-page":"982","DOI":"10.2215\/CJN.06890615","volume":"11","author":"R Provenzano","year":"2016","unstructured":"Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol. 2016;11(6):982\u201391.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"452_CR93","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1080\/0886022X.2020.1811121","volume":"42","author":"B Wang","year":"2020","unstructured":"Wang B, Yin Q, Han YC, Wu M, Li ZL, Tu Y, et al. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients. Ren Fail. 2020;42(1):912\u201325.","journal-title":"Ren Fail"},{"issue":"5","key":"452_CR94","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/MNH.0000000000000431","volume":"27","author":"S Hasegawa","year":"2018","unstructured":"Hasegawa S, Tanaka T, Nangaku M. Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease. Curr Opin Nephrol Hypertens. 2018;27(5):331\u20138.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"452_CR95","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00467-017-3849-3","volume":"34","author":"D Kular","year":"2019","unstructured":"Kular D, Macdougall IC. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics. Pediatr Nephrol. 2019;34(3):365\u201378.","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"452_CR96","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1042\/CS20171625","volume":"132","author":"Y Yang","year":"2018","unstructured":"Yang Y, Yu X, Zhang Y, Ding G, Zhu C, Huang S, et al. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury. Clin Sci (Lond). 2018;132(7):825\u201338.","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"452_CR97","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/0886022X.2021.1915801","volume":"43","author":"AF Miao","year":"2021","unstructured":"Miao AF, Liang JX, Yao L, Han JL, Zhou LJ. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia\/reperfusion injury by inhibiting inflammation. Ren Fail. 2021;43(1):803\u201310.","journal-title":"Ren Fail"},{"issue":"3","key":"452_CR98","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000341870","volume":"36","author":"P Jamadarkhana","year":"2012","unstructured":"Jamadarkhana P, Chaudhary A, Chhipa L, Dubey A, Mohanan A, Gupta R, et al. Treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates ischemic acute kidney injury. Am J Nephrol. 2012;36(3):208\u201318.","journal-title":"Am J Nephrol"},{"issue":"11","key":"452_CR99","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1681\/ASN.2010121249","volume":"22","author":"G Schley","year":"2011","unstructured":"Schley G, Klanke B, Sch\u00f6del J, Forstreuter F, Shukla D, Kurtz A, et al. Hypoxia-inducible transcription factors stabilization in the thick ascending limb protects against ischemic acute kidney injury. J Am Soc Nephrol. 2011;22(11):2004\u201315.","journal-title":"J Am Soc Nephrol"},{"issue":"14","key":"452_CR100","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1042\/CS20210100","volume":"135","author":"M Wu","year":"2021","unstructured":"Wu M, Chen W, Miao M, Jin Q, Zhang S, Bai M, et al. Anti-anemia drug FG4592 retards the AKI-to-CKD transition by improving vascular regeneration and antioxidative capability. Clin Sci (Lond). 2021;135(14):1707\u201326.","journal-title":"Clin Sci (Lond)"},{"issue":"5","key":"452_CR101","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.kint.2019.12.007","volume":"97","author":"S Hasegawa","year":"2020","unstructured":"Hasegawa S, Tanaka T, Saito T, Fukui K, Wakashima T, Susaki EA, et al. The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease. Kidney Int. 2020;97(5):934\u201350.","journal-title":"Kidney Int"},{"issue":"10","key":"452_CR102","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.2337\/db14-0472","volume":"63","author":"L Rahtu-Korpela","year":"2014","unstructured":"Rahtu-Korpela L, Karsikas S, Horkko S, Blanco Sequeiros R, Lammentausta E, Makela KA, et al. HIF prolyl 4-hydroxylase-2 inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction. Diabetes. 2014;63(10):3324\u201333.","journal-title":"Diabetes"},{"issue":"8","key":"452_CR103","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1111\/cas.14524","volume":"111","author":"Y Saito","year":"2020","unstructured":"Saito Y, Takasawa A, Takasawa K, Aoyama T, Akimoto T, Ota M, et al. Aldolase A promotes epithelial-mesenchymal transition to increase malignant potentials of cervical adenocarcinoma. Cancer Sci. 2020;111(8):3071\u201381.","journal-title":"Cancer Sci"},{"issue":"1","key":"452_CR104","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/cvr\/cvs014","volume":"94","author":"M H\u00f6lscher","year":"2012","unstructured":"H\u00f6lscher M, Sch\u00e4fer K, Krull S, Farhat K, Hesse A, Silter M, et al. Unfavourable consequences of chronic cardiac HIF-1\u03b1 stabilization. Cardiovasc Res. 2012;94(1):77\u201386.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"452_CR105","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/FJC.0b013e3181e2bfef","volume":"56","author":"W Bao","year":"2010","unstructured":"Bao W, Qin P, Needle S, Erickson-Miller CL, Duffy KJ, Ariazi JL, et al. Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. J Cardiovasc Pharmacol. 2010;56(2):147\u201355.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"10","key":"452_CR106","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1161\/CIRCULATIONAHA.109.922427","volume":"122","author":"J Moslehi","year":"2010","unstructured":"Moslehi J, Minamishima YA, Shi J, Neuberg D, Charytan DM, Padera RF, et al. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation. 2010;122(10):1004\u201316.","journal-title":"Circulation"}],"container-title":["Current Nutrition Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13668-023-00452-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13668-023-00452-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13668-023-00452-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T21:14:39Z","timestamp":1677618879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13668-023-00452-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,28]]},"references-count":106,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["452"],"URL":"https:\/\/doi.org\/10.1007\/s13668-023-00452-5","relation":{},"ISSN":["2161-3311"],"issn-type":[{"value":"2161-3311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,28]]},"assertion":[{"value":"18 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All figures are drawn by the authors. No need to have any permission from other sources.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Richard J. Johnson and Miguel A. Lanaspa have equity with Colorado Research Partners LLC that is developing inhibitors of fructose metabolism. Dr Johnson also has stocks with XORTX Therapeutics and has received honoraria from Horizon Pharma. All other authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. Not applicable (as this is review article, no human or animal consent is needed).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}